

Please complete this **entire** form and fax it to: **866-940-7328**. If you have questions, please call **800-310-6826**.

**This form may contain multiple pages. Please complete all pages to avoid a delay in our decision.
Allow at least 24 hours for review.**

Section A – Member Information

| | | |
|--|------------|------------|
| First Name: | Last Name: | Member ID: |
| Address: | | |
| City: | State: | ZIP Code: |
| Phone: | DOB: | Allergies: |
| Primary Insurance Information (if any): | | |
| Is the requested medication: <input type="checkbox"/> New or <input type="checkbox"/> Continuation of Therapy? If continuation, list start date: _____ | | |
| Is this patient currently hospitalized? <input type="checkbox"/> Yes <input type="checkbox"/> No If recently discharged, list discharge date: _____ | | |

Section B - Provider Information

| | | |
|---|------------|-------------------|
| First Name: | Last Name: | M.D./D.O. |
| Address: | City: | State: ZIP code: |
| Phone: | Fax: | NPI #: Specialty: |
| Office Contact Name / Fax attention to: | | |

Section C - Medical Information

| | |
|---|--------------|
| Medication: | Strength: |
| Directions for use: | Quantity: |
| Diagnosis (Please be specific & provide as much information as possible): | ICD-10 CODE: |
| Is this member pregnant? <input type="checkbox"/> Yes <input type="checkbox"/> No If yes, what is this member's due date? _____ | |

Section D – Previous Medication Trials

| Medication Name | Strength | Directions | Dates of Therapy | Reason for failure / discontinuation |
|-----------------|----------|------------|------------------|--------------------------------------|
| | | | | |
| | | | | |
| | | | | |
| | | | | |

**Section E – Additional information and Explanation of why preferred medications would not meet the patient's needs:
Please refer to the patient's PDL at www.uhcprovider.com for a list of preferred alternatives**

| | | |
|--------------------|-------------------|-------------|
| Member First name: | Member Last name: | Member DOB: |
|--------------------|-------------------|-------------|

Clinical and Drug Specific Information

PATIENTS LESS THAN 16 YEARS OF AGE

| | |
|--|--|
| <input type="checkbox"/> Yes <input type="checkbox"/> No | Does the prescriber attest they are aware of FDA labeling regarding use of MAT products (Suboxone, buprenorphine, buprenorphine/naloxone, Bunavail, Zubsolv) in patients less than 16 years of age and feels the treatment with the requested product is medically necessary? <i>If yes, list rationale for use:</i> |
|--|--|

SHORT ACTING BUPRENORPHINE WITHOUT NALOXONE

| | |
|--|--|
| <input type="checkbox"/> Yes <input type="checkbox"/> No | Is there documented intolerance to naloxone? <i>If yes, list reason:</i> |
| <input type="checkbox"/> Yes <input type="checkbox"/> No | Is there documented intolerance to naloxone, OR is the patient pregnant or breast feeding? <i>If yes, list reason:</i> |

INITIAL THERAPY (INDUCTION THERAPY)

| | |
|--|--|
| <input type="checkbox"/> Yes <input type="checkbox"/> No | Does the request exceed 24 mg of Suboxone, or equivalent, per day? <i>If yes, list rationale for exceeding 24mg per day:</i> |
| <input type="checkbox"/> Yes <input type="checkbox"/> No | Can the requested dose be achieved by using the plan accepted quantity limit of a different dose or formulation? |

CONTINUATION THERAPY

| | |
|--|--|
| <input type="checkbox"/> Yes <input type="checkbox"/> No | Does the request exceed 16 mg of Suboxone, or equivalent, per day? <i>If yes, list rationale for exceeding 16mg per day:</i> |
| <input type="checkbox"/> Yes <input type="checkbox"/> No | Can the requested dose be achieved by using the plan accepted quantity limit of a different dose or formulation? |

Provider Signature: _____ **Date:** _____

Confidentiality Notice: This transmission contains confidential information belonging to the sender and UnitedHealthcare. This information is intended only for the use of UnitedHealthcare. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action involving the contents of this document is prohibited. If you have received this telecopy in error, please notify the sender immediately.